Study Design and ResultsThis phase III, randomized, double – blind, placebo-controlled, parallel-group clinical study, the efficacy and safety of Teva INS in the treatment of PAR in subjects 12 years or older. At 35 U.S. Clinical sites 470 PAR patients were QNAZE (320 mcg once daily receive receive placebo or as a nasal spray aerosol over a period of six weeks.

Out about the importance of the research Dr. Cretney and L’Oreal Fellowship, Director of WEHI, Professor Suzanne Cory, said: This highly competitive award recognizes Dr. Cretney outstanding research achievements and predicts a bright future for her in Australian medical research. WEHI is proud promoting their further professional development. She added: I congratulate L’Oreal to pursue the promotion of our young women on long-term career in science.The research team at Ume? Department of Medical chemicals and Biophysics hopes to soon be able find the appropriate dosage of acivicin heal permanently permanently cure that infected mice.